Propanc Biopharma, Inc.

Propanc Biopharma, Inc. announced that its CEO, James Nathanielsz, toured a European CDMO's GMP facility to prepare for the production of its lead asset, PRP. This production is crucial for the upcoming Phase 1b, First-In-Human study involving 30-40 advanced cancer patients with solid tumors. Key timelines include preproduction in August 2026, an engineering run in October 2026, and GMP manufacture commencing in December 2026, with a Phase 1B clinical trial application in Australia planned for submission in 2026.

Propanc Biopharma, Inc. has approved a share repurchase program, authorizing the company to buy back up to $5.0 million of its common stock. This decision reflects management's belief that the company is significantly undervalued, especially given recent advancements of its lead asset, PRP, towards a pivotal Phase 1b clinical study for metastatic cancer. The company also highlighted its US FDA Orphan Drug Designation for pancreatic cancer, providing seven-year market exclusivity post-approval, and strategic partnerships. The program aims to enhance shareholder value and signals management's confidence in the company's long-term prospects.

Propanc Biopharma's CEO, James Nathanielsz, attended a keynote address on "Rejuvenation and Health: Science for an Ageing Society" at the University of Granada, featuring renowned scientist Dr. Juan Carlos Izpisúa. Nathanielsz highlighted that Propanc's research into proenzymes for age-related diseases, fibrosis, diabetes, and cancer aligns with this pioneering field. The company also announced that its lead asset, PRP, is on schedule to enter a Phase 1b, First-In-Human study in advanced cancer patients, with ongoing collaborations with the Universities of Granada and Jaén.

Propanc Biopharma, Inc. announced its intention to file a Clinical Trial Application (CTA) in Australia later this year for a Phase 1b, First-In-Human study of its lead asset, PRP. This study will involve 30-40 advanced cancer patients with solid tumors, utilizing an intravenous formulation of PRP administered once weekly. Following the completion of Phase 1, the company plans to conduct two Phase 2 studies, each with 60 patients, targeting pancreatic and ovarian cancers. The CEO also highlighted broader advancements in pancreatic cancer treatment, reinforcing the company's focus on biologically informed strategies.

Propanc Biopharma engaged a European Contract and Development Manufacturing Organization (CDMO) for GMP manufacturing of its lead asset, PRP, for an upcoming Phase 1b First-In-Human clinical study. This pivotal step aims to advance PRP, a proenzyme therapy for advanced solid tumors, into early-stage clinical development. The company plans to file the clinical trial application later this year for the study involving 30-40 advanced cancer patients. PRP, which induces differentiation of cancer cells, previously received USFDA Orphan Drug Designation for pancreatic cancer.

Propanc Biopharma announced corporate progress and third-quarter financial results for the period ended March 31, 2026. The company secured a private placement agreement for up to $100 million to accelerate clinical development, with an initial $2 million already received. Key corporate advancements include executing a service agreement with FyoniBio GmbH for a Phase 1b pharmacokinetics assay and establishing a multi-year anti-aging and cancer research collaboration with Spanish universities. Financially, the company reported a net loss of $6.36 million but significantly reduced total liabilities by $2.10 million and convertible notes to $55,000.

Propanc Biopharma, Inc. reported a net loss of $(6.36) million for the three months ended March 31, 2026, a significant improvement from $(54.07) million in the prior year period. For the nine months ended March 31, 2026, the net loss was $(14.29) million, down from $(54.85) million year-over-year. The company's cash position improved substantially to $443,702, up from $12,088 at June 30, 2025, driven by financing activities including proceeds from common stock sales and Series C preferred stock and warrant exercises.

Propanc Biopharma's Board of Directors approved a 1-for-25 reverse stock split, effective May 18, 2026. This action will reduce the outstanding common shares from approximately 56.96 million to 2.28 million on a pro forma basis. The company is implementing the split to regain compliance with Nasdaq's $1.00 minimum bid price requirement and support its growth plans, including advancing its lead asset PRP to a Phase 1b clinical study.